Keyphrases
Standard of Care
100%
B-cell Maturation Antigen
100%
Myeloma Therapy
100%
Targeted Biologic Therapies
100%
Refractory Myeloma
66%
Protease Inhibitors
33%
Response Rate
33%
Antigen Targeting
33%
Immunosuppressive Agents
33%
Recent Advances
16%
Antibody-antigen
16%
Natural Killer Cells
16%
Targeted Therapy
16%
Line of Therapy
16%
Poor Prognosis
16%
Novel Treatments
16%
Targeted Therapeutics
16%
Side Effect Profile
16%
Plasma Cells
16%
Multiple Classes
16%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Early Phase Clinical Trials
16%
Relapsed or Refractory multiple Myeloma
16%
Penta
16%
Long-term Remission
16%
Antibody-drug Conjugate
16%
Anti-CD38 Monoclonal Antibody
16%
Anti-CD38 Antibody
16%
Therapeutic Class
16%
Bispecific Antibody
16%
Prognosis Treatment
16%
Medicine and Dentistry
Multiple Myeloma
100%
Biological Therapy
100%
B Cell Maturation Antigen
100%
Myeloma
83%
Proteasome Inhibitor
33%
Diseases
33%
Clinical Trial
16%
Monoclonal Antibody
16%
Natural Killer Cell
16%
Chimeric Antigen Receptor T-Cell
16%
Bispecific Antibody
16%
Immunoglobulin Producing Cell
16%
Side Effect
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
B Cell Maturation Antigen
100%
Myeloma
83%
Proteasome Inhibitor
33%
Diseases
33%
Monoclonal Antibody
16%
Clinical Trial
16%
Remission
16%
Chimeric Antigen Receptor
16%
Bispecific Antibody
16%
Side Effect
16%